Chiba University researchers published preclinical results for a cationic nanogel intranasal therapeutic vaccine targeting HPV16 E7 oncoprotein in Science Translational Medicine. The cCHP‑E7 + c‑di‑AMP formulation induced sustained E7‑specific CD4+ and CD8+ T cells in cervicovaginal tissue, slowed tumor growth in mice, and elicited persistent tissue responses in macaques after four doses delivered via a human‑compatible nasal spray device. The vaccine aims to treat established HPV infections and HPV‑driven cervical neoplasia, filling an unmet need beyond prophylactic vaccines. The study names Rika Nakahashi‑Ouchida and Hiromi Mori as lead investigators and provides both mechanistic and translational data, including mucosal T‑cell persistence four months post‑dosing in nonhuman primates. These results support further development toward human trials for a therapeutic HPV vaccine that avoids invasive treatments.